Q1 2023 Earnings Forecast for RAPT Therapeutics, Inc. (NASDAQ:RAPT) Issued By Capital One Financial

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) – Stock analysts at Capital One Financial issued their Q1 2023 earnings per share estimates for shares of RAPT Therapeutics in a note issued to investors on Wednesday, March 15th. Capital One Financial analyst Z. Jallah expects that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($3.08) per share. Capital One Financial also issued estimates for RAPT Therapeutics’ Q2 2023 earnings at ($0.54) EPS, Q3 2023 earnings at ($0.57) EPS, Q4 2023 earnings at ($0.54) EPS, FY2023 earnings at ($2.17) EPS, FY2024 earnings at ($2.70) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at $0.72 EPS and FY2027 earnings at $10.26 EPS.

A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler cut their price objective on shares of RAPT Therapeutics from $34.00 to $33.00 in a research note on Thursday, December 8th. Wells Fargo & Company cut their price target on shares of RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, January 4th. The Goldman Sachs Group reduced their price objective on RAPT Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday. Guggenheim lowered their target price on RAPT Therapeutics from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, HC Wainwright reduced their price target on RAPT Therapeutics from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RAPT Therapeutics presently has an average rating of “Buy” and a consensus target price of $41.38.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $18.94 on Friday. The stock has a market capitalization of $566.50 million, a P/E ratio of -7.34 and a beta of 0.46. RAPT Therapeutics has a one year low of $9.85 and a one year high of $32.45. The firm’s 50 day simple moving average is $27.10 and its two-hundred day simple moving average is $23.30.

Insider Buying and Selling at RAPT Therapeutics

In other news, insider William Ho sold 5,000 shares of the company’s stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $25.56, for a total transaction of $127,800.00. Following the completion of the transaction, the insider now directly owns 35,072 shares of the company’s stock, valued at $896,440.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider William Ho sold 5,000 shares of RAPT Therapeutics stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $25.56, for a total value of $127,800.00. Following the sale, the insider now owns 35,072 shares in the company, valued at $896,440.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Wendye Robbins acquired 2,500 shares of RAPT Therapeutics stock in a transaction on Tuesday, March 14th. The shares were bought at an average cost of $18.99 per share, for a total transaction of $47,475.00. Following the completion of the transaction, the director now owns 14,900 shares in the company, valued at approximately $282,951. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 20,742 shares of company stock worth $532,352. 5.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors have recently bought and sold shares of the stock. Swiss National Bank grew its holdings in shares of RAPT Therapeutics by 7.6% during the 1st quarter. Swiss National Bank now owns 45,400 shares of the company’s stock worth $998,000 after acquiring an additional 3,200 shares during the period. JPMorgan Chase & Co. grew its stake in RAPT Therapeutics by 23.7% in the first quarter. JPMorgan Chase & Co. now owns 13,575 shares of the company’s stock worth $299,000 after purchasing an additional 2,599 shares during the period. MetLife Investment Management LLC grew its stake in RAPT Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 11,028 shares of the company’s stock worth $243,000 after purchasing an additional 4,070 shares during the period. Rhumbline Advisers raised its holdings in RAPT Therapeutics by 18.3% in the first quarter. Rhumbline Advisers now owns 21,961 shares of the company’s stock worth $483,000 after purchasing an additional 3,405 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in RAPT Therapeutics by 32.0% during the first quarter. Dimensional Fund Advisors LP now owns 285,325 shares of the company’s stock valued at $6,274,000 after buying an additional 69,238 shares during the period.

RAPT Therapeutics Company Profile

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.